invest1 publisher
Aimed Bio targets 15 clinical trials by 2030, holds 84.2 billion won in available assets
Aimed Bio is adding antibody-oligonucleotide conjugates and brain disease to a pipeline built on ADCs, and it is paying for the expansion out of milestone payments triggered by other companies' trials.
Publishers:en.sedaily.com
Reality
- Evidence36
- Adoption46
- Hype gap+34
- Incentives76
- Confidence42